Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 12/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19858188 | 0.94 | MAPT (0.42) | MAPTALDH1A1CYP1A2CYP2C19HTT | |
| SCHEMBL18075062 | 0.91 | HCAR3 (0.48) | MAPTALDH1A1CYP1A2CYP2C19HTT | |
| SCHEMBL19858206 | 0.87 | MAPT (0.46) | MAPTALDH1A1CYP1A2CYP2C19HTT | |
| SCHEMBL28505091 | 0.86 | MAPT (0.44) | MAPTALDH1A1CYP1A2CYP2C19HTT | |
| SCHEMBL18075301 | 0.85 | HCAR3 (0.46) | MAPTALDH1A1HTTHCAR3KMT2A | |
| SCHEMBL18075569 | 0.84 | PTGER4 (0.44) | MAPTALDH1A1CYP1A2CYP2C19HTT | |
| SCHEMBL19857884 | 0.82 | MAPT (0.61) | MAPTALDH1A1CYP1A2CYP2C19HTT | |
| SCHEMBL19857882 | 0.82 | MAPT (0.61) | MAPTALDH1A1CYP1A2CYP2C19HTT | |
| SCHEMBL18074977 | 0.79 | HCAR3 (0.43) | MAPTALDH1A1CYP1A2CYP2C19HTT | |
| SCHEMBL19858087 | 0.79 | HCAR3 (0.60) | MAPTALDH1A1CYP1A2CYP2C19HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11053212-B2 | Benzimidazole derivatives as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-07-06 | — | — | US | disclosed |
| CN-107635989-B | Benzimidazole derivatives as bromodomain inhibitors | 葛兰素史克知识产权开发有限公司 | 2020-12-08 | — | — | CN | disclosed |
| US-20200039953-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-02-06 | — | — | US | disclosed |
| US-10442786-B2 | Benzimidazole derivatives as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-10-15 | — | — | US | disclosed |
| EP-3549939-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-10-09 | — | — | EP | disclosed |
| EP-3271349-B1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-05-15 | — | — | EP | disclosed |
| US-20180044317-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-02-15 | — | — | US | disclosed |
| EP-3271349-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2018-01-24 | — | — | EP | disclosed |
| WO-2016146738-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10442786-B2 | Benzimidazole derivatives as bromodomain inhibitors | BRD4, BRD1, BRPF3 | MAPT 3681/4885ALDH1A1 2160/4885CYP1A2 3263/4885 |
| US-20200039953-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD1, BRPF3 | MAPT 3681/4885ALDH1A1 2160/4885CYP1A2 3263/4885 |
| US-20180044317-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD1, BRPF3 | MAPT 3681/4885ALDH1A1 2160/4885CYP1A2 3263/4885 |
| US-11053212-B2 | Benzimidazole derivatives as bromodomain inhibitors | BRD4, BRD1, BRPF3 | MAPT 3681/4885ALDH1A1 2160/4885CYP1A2 3263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.